PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies ...

One participant’s biopsy was not collected at day 28 due to pseudoaneurysm in connection with the biopsy procedure. One participant’s sample showed a splicing index outside the pre-specified ...

– The Company today reported positive initial results from the ongoing FREEDOM-DM1 trial in patients with DM1; mean splicing correction of 12.3% and 29.1% in 5 and 10 mg/kg cohorts, respectively ...

J Gastroenterol Hepatol. 2009;24(4):509-519. One of the most important issues may be the introduction of rapid staining performed by a cytopathologist or cytotechnician during the procedure ...

PepGen Inc. , a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological ...